Editas Medicine, Inc. (EDIT) saw its loss widen to $39.38 million, or $1.10 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $12.63 million, or $4.05 a share. Revenue during the quarter grew 13.38 percent to $0.90 million from $0.79 million in the previous year period.
Operating loss for the quarter was $38.98 million, compared with an operating loss of $12.37 million in the previous year period.
"In three years, we have established an unparalleled position for developing genome editing medicines," said Katrine Bosley, president and chief executive officer of Editas Medicine. "In 2016, we significantly broadened our scientific platform with CRISPR/Cpf1 and advanced forms of CRISPR/Cas9, demonstrated proof-of-editing in vivo for our most advanced program in LCA10, and expanded our leadership team with the addition of our Chief Scientific Officer and Chief Medical Officer."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
